CytRx Corp. shares fell 9 percent Tuesday after the company announced the U.S. Food and Drug Administration had placed a hold on enrolling new patients in clinical trials of its experimental cancer drug following the death of a patient.
The advanced-stage cancer patient was not part of the West L.A. pharmaceutical company’s trial group. The patient received the drug, aldoxorubicin, through a program that makes experimental drugs available to patients with serious diseases who do not qualify for the trials.
Patients already enrolled in the mid-stage trials will continue receiving the treatment, CytRx said, but no new patients can be enrolled until the FDA hold is lifted.
Aldoxorubicin combines an established chemotherapy drug, doxorubicin, with a molecule that enables higher levels of doxorubicin to be safely given to patients without endangering healthy tissue.
Shares of CytRx Corp. fell 24 cents in Tuesday trading to close at $2.52.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Drug Maker’s Stock Falls After Death of Patient
- CytRx Shares Rise on Cancer Drug Data
- Clinical Trials Help Revive Drug Developer’s Stock
- Poor Prognosis for Drug Developer’s Stock Offering
- CytRx Rises on Cancer Drug Trials
- Medical Center Will Put New Partnership to Tests
- CytRx Licenses Cancer Drug to NantCell; Asks Shareholders for Reverse Stock Split
- CytRx Shares Spike on Trial Results